Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.55 |
| ▸ | DRD3 | P35462 | 1/20 | 0.55 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.49 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.49 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.49 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.49 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.49 |
| ▸ | CCR5 | P51681 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 5/20 | 0.44 |
| ▸ | BACE1 | P56817 | 5/20 | 0.44 |
| ▸ | BCHE | P06276 | 4/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13916012 | 0.84 | FUCA1 (0.56) | DRD2DRD3FUCA1ACHE | |
| SCHEMBL1972330 | 0.84 | FUCA1 (0.56) | DRD2DRD3FUCA1ACHE | |
| Hydrochloric Acid SCHEMBL4410761 | 0.82 | FUCA1 (0.55) | DRD2DRD3FUCA1ACHE | |
| SCHEMBL5996694 | 0.81 | CHRNB2 (0.49) | DRD2DRD3FUCA1CHRNB2CHRNB4 | |
| Hydrochloric Acid SCHEMBL5997163 | 0.80 | CHRNB2 (0.48) | DRD2DRD3FUCA1CHRNB2CHRNB4 | |
| SCHEMBL147328 | 0.73 | DPP4 (0.63) | DRD2DRD3FUCA1CCR5ACHE | |
| SCHEMBL1895840 | 0.73 | DRD2 (0.53) | DRD2DRD3FUCA1CCR5DPP4 | |
| SCHEMBL147329 | 0.73 | DPP4 (0.63) | DRD2DRD3FUCA1CCR5ACHE | |
| SCHEMBL1896647 | 0.73 | DRD2 (0.56) | DRD2DRD3FUCA1CCR5ACHE | |
| SCHEMBL1725958 | 0.73 | DPP4 (0.63) | DRD2DRD3FUCA1CCR5ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1044189-B2 | ARYL FUSED AZAPOLYCYCLIC COMPOUNDS | PFIZER PROD INC (US) | 2015-02-25 | — | — | EP | disclosed |
| EP-1619192-B1 | ARYL FUSED AZAPOLYCYCLIC COMPOUNDS | PFIZER PROD INC (US) | 2009-12-30 | — | — | EP | disclosed |
| EP-1044189-B1 | ARYL FUSED AZAPOLYCYCLIC COMPOUNDS | PFIZER PROD INC (US) | 2008-02-13 | — | — | EP | disclosed |
| US-20070275973-A1 | ARYL FUSED AZAPOLYCYCLIC COMPOUNDS | PFIZER INC | 2007-11-29 | — | — | US | disclosed |
| US-7205300-B2 | Aryl fused azapolycyclic compounds | PFIZER INC (US) | 2007-04-17 | — | — | US | disclosed |
| US-7144882-B2 | Aryl fused azapolycyclic compounds | PFIZER INC (US) | 2006-12-05 | — | — | US | disclosed |
| EP-1259489-B1 | ARYL FUSED AZAPOLYCYCLIC COMPOUNDS | PFIZER PROD INC (US) | 2006-06-07 | — | — | EP | disclosed |
| EP-1659114-A2 | PROCESS FOR THE PREPARATION OF BICYCLO[3.2.1]OCTANE FUSED WITH QUINAZOLINE DERIVATIVES | Pfizer Products Inc. (US) | 2006-05-24 | — | — | EP | disclosed |
| EP-1619192-A2 | Aryl fused azapolycyclic compounds | Pfizer Products Inc. (US) | 2006-01-25 | — | — | EP | disclosed |
| US-6897310-B2 | Aryl fused azapolycyclic compounds | PFIZER INC (US) | 2005-05-24 | — | — | US | disclosed |
| US-6887884-B2 | Aryl fused azapolycyclic compounds | PFIZER INC (US) | 2005-05-03 | — | — | US | disclosed |
| US-6605610-B1 | Reducing nicotine addiction; treating neurological and psychological disorders | PFIZER INC | 2003-08-12 | — | — | US | disclosed |
| US-20030130260-A1 | Aryl fused azapolycyclic compounds | COE JOTHAM WADSWORTH (US) | 2003-07-10 | — | — | US | disclosed |
| US-20020132824-A1 | Aryl fused azapolycyclic compounds | COE JOTHAM WADSWORTH (US) | 2002-09-19 | — | — | US | disclosed |
| US-6410550-B1 | Aryl fused azapolycyclic compounds | PFIZER INC | 2002-06-25 | — | — | US | disclosed |
| US-20020072524-A1 | Aryl fused azapolycyclic compounds | WADSWORTH JOTHAM (US) | 2002-06-13 | — | — | US | disclosed |
| US-20020072525-A1 | Aryl fused azapolycyclic compounds | PFIZER INC | 2002-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020132824-A1 | Aryl fused azapolycyclic compounds | GRIN2C, GRIN2A, GRIN2B | DRD2 27/4885DRD3 46/4885FUCA1 2280/4885 |
| US-20030130260-A1 | Aryl fused azapolycyclic compounds | GRIN2C, GRIN2A, GRIN3A | DRD2 75/4885DRD3 82/4885FUCA1 2025/4885 |
| US-20020072524-A1 | Aryl fused azapolycyclic compounds | GRIN2C, GRIN2A, GRIN2B | DRD2 27/4885DRD3 46/4885FUCA1 2280/4885 |
| US-20070275973-A1 | ARYL FUSED AZAPOLYCYCLIC COMPOUNDS | GRIN2C, GRIN2A, GRIN2B | DRD2 19/4885DRD3 74/4885FUCA1 3531/4885 |
| US-20020072525-A1 | Aryl fused azapolycyclic compounds | GRIN2C, GRIN2A, GRIN2B | DRD2 27/4885DRD3 46/4885FUCA1 2280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.